Definition	definition	O	O	O	O
and	and	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
infected	infected	O	O	OTHERS	I
with	with	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C	c	O	DISEASE	OTHERS	I
virus	virus	O	O	OTHERS	I
.	.	O	O	O	O

Chronic	chronic	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
with	with	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C	c	O	DISEASE	OTHERS	I
virus	virus	O	O	OTHERS	I
(	(	O	O	O	O
HCV	hcv	O	O	O	O
)	)	O	O	O	O
can	can	O	O	O	O
progress	progress	O	O	O	O
to	to	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
hepatocellular	hepatocellular	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
end-stage	end-stage	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
current	current	O	O	O	O
best	best	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
HCV	hcv	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
is	is	O	O	O	O
combination	combination	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
pegylated	pegylated	O	O	OTHERS	I
interferon	interferon	O	O	OTHERS	I
and	and	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
this	this	O	O	O	O
regimen	regimen	O	O	O	O
produces	produces	O	O	O	O
sustained	sustained	O	O	O	O
virologic	virologic	O	O	O	O
responses	responses	O	O	O	O
(	(	O	O	O	O
SVRs	svrs	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
approximately	approximately	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
potentially	potentially	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Hemoglobin	hemoglobin	O	O	O	O
concentrations	concentrations	O	O	O	O
decrease	decrease	O	O	O	O
mainly	mainly	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
of	of	O	O	O	O
ribavirin-induced	ribavirin-induced	O	O	O	O
hemolysis	hemolysis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
this	this	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
can	can	O	O	O	O
be	be	O	O	O	O
problematic	problematic	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
HCV	hcv	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
,	,	O	O	O	O
especially	especially	O	O	O	O
those	those	O	O	O	O
who	who	O	O	O	O
have	have	O	O	O	O
comorbid	comorbid	O	O	O	O
renal	renal	O	O	O	O
or	or	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
disorders	disorders	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
general	general	O	O	O	O
,	,	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
can	can	O	O	O	O
increase	increase	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
negative	negative	O	O	O	O
effects	effects	O	O	O	O
on	on	O	O	O	O
cerebral	cerebral	O	O	O	O
function	function	O	O	O	O
and	and	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
ribavirin-associated	ribavirin-associated	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
can	can	O	O	O	O
be	be	O	O	O	O
reversed	reversed	O	O	O	O
by	by	O	O	O	O
dose	dose	O	O	O	O
reduction	reduction	O	O	O	O
or	or	O	O	O	O
discontinuation	discontinuation	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
approach	approach	O	O	O	O
compromises	compromises	O	O	O	O
outcomes	outcomes	O	O	O	O
by	by	O	O	O	O
significantly	significantly	O	O	O	O
decreasing	decreasing	O	O	O	O
SVR	svr	O	O	O	O
rates	rates	O	O	O	O
.	.	O	O	O	O

Recombinant	recombinant	O	O	O	O
human	human	O	O	O	O
erythropoietin	erythropoietin	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
manage	manage	O	O	O	O
ribavirin-associated	ribavirin-associated	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
but	but	O	O	O	O
has	has	O	O	O	O
other	other	O	O	O	O
potential	potential	O	O	O	O
disadvantages	disadvantages	O	O	O	O
.	.	O	O	O	O

Viramidine	viramidine	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
liver-targeting	liver-targeting	O	O	O	O
prodrug	prodrug	O	O	O	O
of	of	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
has	has	O	O	O	O
the	the	O	O	O	O
potential	potential	O	O	O	O
to	to	O	O	O	O
maintain	maintain	O	O	O	O
the	the	O	O	O	O
virologic	virologic	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
while	while	O	O	O	O
decreasing	decreasing	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C.	c.	O	O	O	O

